Dr Reddy's launches Paricalcitol Injection in the US


Dr. Reddy's Laboratoriesannounced that it has launched Paricalcitol Injection, USP, in 2 mcg, 5 mcg, 10 mcg, a therapeutic equivalent generic version of Zemplar (paricalcitol) Injection in the United States market approved by the US Food & Drug Administration (USFDA).

The Zemplar brand and generic had US sales of approximately $22.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health.

Dr. Reddy's Paricalcitol Injection is available in 2 mcg, 5 mcg, and 10 mcg, and is the first ANDA product launched in the US market.

Zemplar is a registered trademark of ABBVIE Inc.



Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email